Infinity BiologiX and Cytox Collaborate to Provide New Genetic Test to Predict the Risk of Cognitive Decline Due to Alzheimer’s Disease
Retrieved on:
Wednesday, June 23, 2021
Health, Genetics, General Health, Clinical trials, Research, Science, Biotechnology, Medicine, Branches of biology, Clinical medicine, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Medical genetics, Medical tests, Genetic testing, Alzheimer's disease, Disease, Dementia, Infinity BiologiX (IBX):, Cytox, genoSCORE™, INFINITY BIOLOGIX (IBX):, CYTOX, GENOSCORE™
Today, Infinity BiologiX, LLC (IBX) and Cytox Ltd, announce a collaboration to provide a new, non-invasive, genetic test that can predict the risk of cognitive decline due to Alzheimers through a simple saliva or blood sample.
Key Points:
- Today, Infinity BiologiX, LLC (IBX) and Cytox Ltd, announce a collaboration to provide a new, non-invasive, genetic test that can predict the risk of cognitive decline due to Alzheimers through a simple saliva or blood sample.
- Dr. Richard Pither, CEO of Cytox, commented: Alzheimers disease affects over 46 million people in the world1.
- genoSCORE is a new non-invasive, genetic test to predict future risk of cognitive decline due to Alzheimers disease (AD).
- This test is a measure of relative risk for future onset of Late-onset Alzheimers disease (LOAD) and should not be considered as standalone diagnostic test.